PTC Therapeutics PTCT Equity Securities, FV-NI, Realized Gain (Loss)

Equity Securities, FV-NI, Realized Gain (Loss) at other companies

MastercardMA

-$66M-128%

Hewlett Packard EnterpriseHPE

-$36.75M-1,031%

ProgressivePGR

$11M+83.3%

BlockXYZ

-$5.67M-4,396%

KrogerKR

-$101M-405%

Phillips 66PSX

-$9M+10.0%

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiRealizedGainLoss.

The official record: PTC Therapeutics’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's equity securities, fv-ni, realized gain (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's equity securities, FV-NI, realized gain (loss)?: PTC Therapeutics (PTCT) reported equity securities, FV-NI, realized gain (loss) of $1.1M in Q4 2023.